# Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir

> **NCT03374358** · PHASE4 · COMPLETED · sponsor: **Helsinki University Central Hospital** · enrollment: 45 (actual)

## Conditions studied

- HIV Seropositivity
- Metabolic Syndrome
- Fatty Liver

## Interventions

- **DRUG:** Raltegravir

## Key facts

- **NCT ID:** NCT03374358
- **Lead sponsor:** Helsinki University Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-10
- **Primary completion:** 2019-11-02
- **Final completion:** 2019-11-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03374358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03374358, "Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03374358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*